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AbSTRACT
With the aging of the world’s population, the prevalence of 
age-related diseases is continually increasing, especially os-
teoarthritis, the most common form of joint disease. In addi-
tion to its high prevalence, osteoarthritis has been correlated 
with high medical and social costs. Among the treatment 
methods, viscosupplementation (intra-articular injection of 
hyaluronic acid derivatives) has been gaining more prominen-
ce. The substances used are high molecular weight polysac-
charides that, in addition to mechanical functions of weight 
distribution and joint lubrication, have anti-inflammatory 
properties and physical-chemical action on a variety of joint 
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INTRODUCTION
Osteoarthritis, the commonest form of joint disease, 
is a condition of multifactorial origin that leads to 
joint cartilage degeneration and affects all components 
of the joint. It is a slow, progressive and debilitating 
process, with high prevalence in the adult population. 
Around 40% of individuals over the age of 65 years in 
the United Kingdom suffer from symptoms associated 
with osteoarthritis of the knees or hips(1).
There are more than 50 types of treatment for go-
narthritis(2). The main non-surgical treatment options 
include pharmacological management using analgesics, 
non-steroidal anti-inflammatory drugs (NSAIDs)(2,3), 
oral corticosteroids and disease-modifying drugs for 
osteoarthritis (DMDOA)(4), especially glucosamine, 
chondroitin, avocado and soybean unsaponifiable ex-
tracts and diacerhein; orthoses(5,6), acupuncture, phy-
siotherapy, body and mind therapies(2,7), intra-articular 
corticosteroid injections(8) and intra-articular hyaluronic 
acid injection (viscosupplementation)(9,10).
VISCOSUPPLEMENTATION
Properties
Viscosupplementation consists of injection of 
exogenous hyaluronic acid into diarthrodial joints, 
with the aim of restoring the rheological properties 
of the synovial fluid, thereby producing mechani-
cal, analgesic, anti-inflammatory and chondropro-
tective effects. Hyaluronic acid is a high-viscosity 
polysaccharide that is produced naturally by the B 
cells of the synovial membrane. From a bioche-
mical point of view, it is classified in the glycosa-
minoglycan (GAG) group(11). Under physiological 
conditions, it behaves like a salt and is therefore 
named sodium hyaluronate or hyaluronan(12). Its 
physicochemical properties are determined by its 
molecular weight and spatial shape. High molecu-
lar weight molecules of hyaluronic acid interlink 
to form a high-viscosity solution that serve both as 
a lubricant and as a shock absorber(13).
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characteristics. These effects are directly proportional to the 
molecular weight and concentration of the drug used and any 
cross-links that may be present in the drug. Viscosupplemen-
tation is a simple procedure and can be performed in outpa-
tient clinics. It provides benefits regarding pain and function, 
and also favorably alters the course of the disease, through 
quantitatively and qualitatively improving the joint cartilage. 
It has a good safety profile and favorable cost-effectiveness 
relationship, and is indicated both for osteoarthritis cases and 
after an arthroscopic procedure.
Keywords – Hyaluronic Acid/administration & dosage; 
Hyaluronic Acid/therapeutic use; Osteoarthritis 
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mechanism of action
Osteoarthritic joints present high activation of 
synoviocytes, which produce a variety of  cytokines 
and enzymes related to this disease, such as interleukin 
(IL)-ß1, IL-6, IL-8, TNF-alpha, metalloproteinases, 
aggrecanases and nitric oxide (NO)(14). Hyaluronic 
acid is an important modulator, especially through 
interaction with CD44 receptors that are present 
in fibroblast-like synoviocytes(15). Therefore, in 
addition to the mechanical effects of promoting better 
force distribution, diminishing the pressure due to 
weight(16) and recovering the rheological properties 
of the synovial fluid(17), hyaluronic acid also acts 
biochemically. It diminishes the gene expression 
of the cytokines and enzymes that are associated 
with osteoarthritis(14), and diminishes prostaglandin 
production(18) and the intra-articular metalloproteinase 
concentration(19). Its presence stimulates greater 
production of hyaluronic acid by the synoviocytes(20); 
it has an analgesic effect, thereby diminishing nerve 
impulses and the sensitivity of nociceptive nerve 
ends(21,22); stabilizes the cartilaginous matrix(23); 
stimulates chondrocyte proliferation; it increases 
type 2 collagen and aggrecan production by 
chondrocytes(24); and diminishes the degradation of 
type 2 collagen(25).
Structural benefit
The structural benefit of viscosupplementation 
has been seen through second-look arthroscopy, 
performed one year after treatment started, in 
which the joint surface was seen to have a bet-
ter visual appearance, compared with a placebo 
group(26). Increased cartilage volume was observed 
by means of imaging examinations; and biopsies 
performed before and after viscosupplementation 
showed that, six months later, the surface layer had 
been reconstituted, with better matrix quality, hi-
gher chondrocyte density and greater numbers of 
organelles inside(27). Diminished loss of joint space 
was observed one year after the procedure, also in 
comparison with the placebo group(28). From an 
economic point of view, there are increasing num-
bers of studies demonstrating that if viscosupple-
mentation is incorporated into treatments for knee 
osteoarthritis, it may present a good cost-effective-
ness relationship, including the capacity to delay a 
total knee arthroplasty(29-31).
Synthesis
Exogenous hyaluronic acid is produced from two 
sources:
• Avian origin: from poultry material (cock crest). 
This presents allergenic potential due to avian anti-
gens. The following avian products are on the Brazil-
ian market: Polireumin® (=Hyalgan®) and Synvisc®/ 
Synvisc® One™; or
• Non-avian origin: Bio-fermentation products using 
bacteria (Streptococcus zooepidermicus). These have 
lower allergenic potential. The following non-avian 
products are on the Brazilian market: Suprahyal® 
(=Adant®), Suplasyn®, Orthovisc®, Osteonil® (=Os-
tenil®), Durolane® and Viscoseal®.
In addition, in relation to hyaluronic acid synthesis, 
these substances can be classified into two types:
• hyaluronans: Long-chain molecules of avian or bio-
fermenation origin, with a molecular weight of be-
tween 0.5 and 1.8 x 106 Da (Polireumin®, Suplasyn®, 
Fermathron®, Orthovisc®, Osteonil® and Viscoseal®);
• hylan: hyaluronan molecule chemically modified by 
means of cross-links, with a liquid phase of higher 
molecular weight (around 6x106 Da), through cross-
linking connections between long chains of hyaluro-
nan, and a solid portion (of infinite molecular weight) 
formed by even greater presence of links (Synvisc®). 
molecular weight
In relation to molecular weight, although all the 
hyaluronic acids used in orthopedics can be considered 
to have high molecular weight, the current products 
can be classified as:
• “Low molecular weight”, i.e. between 0.5 and 1 x 106 
Da, including: Suplasyn®, Polireumin® (=Hyalgan®), 
Fermathron®, and Suprahyal® (=Adant®);
“Intermediate molecular weight”, i.e. between 1 and 
1.8 x 106 Da, including: Osteonil® (Ostenil®), Ortho-
visc®, Durolane® and Viscoseal®; or
• “High molecular weight”, i.e. 6 x 106 Da: Synvisc® 
and Synvisc®One™.
The molecular weight, concentration and presence of 
cross-links on the viscossuplementation(32) results. Ho-
wever, this topic continues to be a matter of controver-
sy. In relation to the protective physicochemical func-
tions of hyaluronic acid, most of the abovementioned 
studies indicate that the effect is directly proportional 
to the molecular weight. However, a large proportion 
of these studies were in vitro experiences, and some
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authors believe that the in vivo effects will not be the 
same, given that precisely the excessive molecular 
size (between 1 and 6 x 106 Da) would prevent hya-
luronic acid from moving from the intra-articular en-
vironment to the intercellular environment, such that 
it would not have the capacity to act on synoviocytes 
and chondrocytes(33). According to these authors, pro-
ducts with molecular weight between 0.5 and 1 x 106 
Da would have the best in vivo effects. However, 
because of the great heterogeneity between studies, 
the principal reviews and guidelines have not shown 
any advantage for any product over any other(2,9,10). 
In relation to pain, it can be affirmed with greater 
certainty that both the in vitro results and the in vivo 
results indicate that there is a direct relationship be-
tween molecular weight and analgesia.
Indications
Viscosupplementation is indicated for treating 
osteoarthritis, in order to recover the rheological 
properties of the synovial fluid, achieve analgesia, 
improve function and regenerate the joint cartilage 
articular. It is also indicated after arthroscopy.
Practically any osteoarthritic joint can be infiltrated. 
The great majority of studies have been on knees, but 
intra-articular injection of hyaluronic acid has also pre-
sented good results in hips, shoulders, ankles, elbows, 
hand and feet(34,35). Viscosupplementation is done as an 
outpatient procedure, and the application method has 
only been well established for knees. It is still a matter 
for discussion in relation to other joints, for which the 
quantity to be applied and the frequency of applications 
will depend on the characteristics of the product and 
the experience of the professional.
In knees, hylan G-F 20 is the only drug that 
enables a single application of 6 ml (three  injections 
of Synvisc® Classic or one injection of Synvisc® 
One™))(36). On the other hand, with hyaluronans, one 
injection per week should be applied, for three to five 
weeks(9,37). Sodium hyaluronate has an intra-articular 
half-life of 13 hours, while the half-life of hylan G-F 
20 is 1.5 days (liquid phase) and 8.8 days (solid phase), 
probably because of the presence of cross-links. This 
may explain why good results were obtained with only 
one application(38). One study reported application of 
three doses of a hyaluronate of 1.3 x 106 Da (15 mg/
ml; 2 ml per injection; Orthovisc®) immediately after 
arthroscopy, and showed that there was an improvement 
in the results from arthroscopy through intra-articular 
injection of hyaluronic acid(39). However, other than 
hylan G-F 20, no other presentation available in Brazil 
has been used to study the effect of injecting multiple 
doses, as one, two or three injections per week, in 
order to really prove that the agent can be injected in 
a single dose with equal or superior results. 
On the other hand, intra-articular injection of 
hyaluronic acid of two million Daltons diluted in 10 ml 
(Viscoseal®) immediately after arthroscopy showed that 
the functional and analgesic results obtained through 
arthroscopy were maintained up to two years after the 
arthroscopy, and much more so in the injected group 
than in the group that only underwent the operation(40). 
Arthroscopy washes away the layer of hyaluronic acid 
that covers the cartilage and synovial membrane and 
protects the underlying tissues from damage due to 
free radicals and other destructive elements. A few 
days are needed for the synovium to start producing 
this hyaluronic acid again. Viscosupplementation after 
arthroscopy has the function of replacing this film, as 
well as the analgesic and anti-inflammatory properties 
already cited, thereby diminishing the inflammatory 
pain caused by surgical aggression. The main care 
to be taken here is to close the arthroscopic portals 
well, because this anti-inflammatory property of 
hyaluronic acid injected after arthroscopy will inhibit 
the inflammatory healing response and may give rise 
to a synovial fistula through the arthroscopic portal. 
RESULTS
The clinical results from viscosupplementation 
are important and its benefit has now been well es-
tablished. Meta-analyses and systematic reviews 
have proven its efficacy, with statistical significance 
shown in comparison with placebo. The best results 
from viscosupplementation occur between the fifth 
and thirteenth weeks. Viscosupplementation has also 
been shown to be more effective than intra-articular 
injection of corticosteroids, particularly from the fifth 
week onwards. Over the first four weeks, it is not su-
perior, probably because of the fast and potent action 
of corticosteroids, which act to directly paralyze the 
inflammatory action of the joint, while hyaluronic 
acid has a role that is considered to be more “modu-
latory”. However, the benefits from infiltration with 
corticosteroids disappear after two to four weeks and, 
from the fifth week onwards, there is already a sta-
tistically significant difference favoring viscosupple-
Rev Bras Ortop. 2012;47(2):160-4
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mentation. The benefit from this may last from six 
months to two years. It is known that using drug as-
sociations, i.e. infiltration of corticosteroids together 
with hyaluronic acid, improves the initial results from 
viscosupplementation(41). It is also known that this 
alleviates pain better than using acetaminophen and 
that it has a treatment effect similar to use of COX2 
inhibitors (from the point of view of analgesia)(42,43).
It is known that the patients who would benefit 
most from this treatment are those whose disease is 
at an initial stage (low degrees of osteoarthritis) and 
who use their joints more actively. Prior joint washing 
improves the results(44), as does correctly respecting 
the application regime, according to the type of hyalu-
ronic acid used. The intra-articular positioning of the 
needle at the moment of the infiltration is fundamen-
tal, and injection of medication outside of the interior 
of the joint has been put forward as the main cause 
of poor results. Adverse effects may occur in around 
4.2% of the patients, and these present as effusions, 
arthralgia, heat and joint erythema(45). In such cases, 
as in any acute arthritis crisis, the treatment should 
consist of ice, rest, limb elevation and use of anti-
-inflammatory medication, if not contraindicated. If 
necessary, the joint can be punctured. Analysis on the 
synovial fluid will confirm that these are not cases 
of infection. After controlling the allergic or inflam-
matory reaction, the effect of viscosupplementation 
remains. Pseudo-sepsis, i.e. prominent aseptic syno-
vitis with heat and large-scale joint effusion (which 
may occur after infiltration), seems to occur more 
frequently with hylan infiltration and with infiltration 
of hyaluronan of avian origin. It is not known whether 
this is due to cross-links of the hylan, or an allergic 
reaction to avian’s proteins. Nonetheless, there is no 
doubt that the other complications are more related to 
infiltration of hyaluronic acid that does not take place 
into the joint space.
FINAL REMARKS
It is fundamental to bear in mind that the Osteoar-
thritis treatment is multimodal. The causes of osteoar-
thritis need to be identified, along with its severity. Me-
chanical deviations should be corrected. Medications 
do not compensate for deviation from the axis. Patients 
need to be educated about their disease and stimulated 
to take active measures regarding their treatment. The 
disease does not have a cure, but it can be controlled 
through the diet, physical exercise, use of orthoses and 
administration of medications. The usual treatment for 
osteoarthritis is improved through addition of viscosu-
pplementation, which is cost effective. We do not know 
whether there is any better product, but we know that 
there are products with different characteristics. We be-
lieve that it is important for physicians to know about 
the hyaluronic acid that they intend to use and thus to 
respect its characteristics. Physicians need to bear in 
mind what their objectives are (analgesia, chondropro-
tection, practicality or safety), in order to optimize the 
viscosupplementation as much as possible. In 2012, it 
is expected that a Brazilian study showing that visco-
supplementation is also cost effective in this country 
will be presented.
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